Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), relating to its proposed sale to Gurnet Point Capital and Novo Holdings A/S. Under the terms of the agreement, PRTK shareholders are expected to receive $2.15 in cash per share they own and a contingent value right worth up to $0.85 per share.